Reify Health, a company dedicated to shortening clinical trial timelines, announced today that it raised $220 million in a Series C financing round.
Coatue Management led the round, with Iconiq Growth and Adams Street Partners joining along with existing investors Sierra Ventures and Battery Ventures. The round brings the company’s valuation to $2.2 billion, according to a news release.
Boston-based Reify Health built a foundation for running clinical trials through its StudyTeam and Care Access business entities. StudyTeam optimizes patient recruitment and enrollment, with companies such as Amgen, AstraZeneca, Eli Lilly and more using the platform.
Care Access has conducted the most advanced decentralized trials at scale, Reify Health said, and is the world’s leading decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers and communities.
Reify Health said it plans to us…